Actuate Therapeutics (ACTU) Other financing activities (2024 - 2025)
Actuate Therapeutics (ACTU) posted quarterly Other financing activities of $4.6 million for Q4 2025, down 80.83% year-over-year from $24.0 million in Q4 2024, and up 13561.71% quarter-over-quarter from -$34115.0 in Q3 2025.
Actuate Therapeutics (ACTU) Other financing activities (2024 - 2025) Analysis & Trends
Actuate Therapeutics (ACTU) has reported Other financing activities for 2 consecutive years, with $4.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Other financing activities fell 80.83% year-over-year to $4.6 million; the TTM figure through Dec 2025 stood at $24.0 million (changed N/A YoY), while the FY2025 annual figure was $4.6 million, down 80.83% from the prior year.
- Other financing activities rose to $4.6 million in Q4 2025 per ACTU's latest filing, from -$34115.0 in the prior quarter.
- Across five years, Other financing activities topped out at $24.0 million in Q4 2024 and bottomed at -$4.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Actuate Therapeutics | 30.08 Mn | 30.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.59 Mn |
| Dec 31, 2025 | 4.59 Mn |
| Sep 30, 2025 | -34,115.00 |
| Sep 30, 2025 | -34,115.00 |
| Jun 30, 2025 | -4.56 Mn |
| Jun 30, 2025 | -4.56 Mn |
| Dec 31, 2024 | 23.96 Mn |
| Dec 31, 2024 | 23.96 Mn |